Clinical Trial

Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is a single-center, single-arm, open-label, exploratory clinical trial. A total of 30 patients with diffuse cutaneous systemic sclerosis (dcSSc) will be enrolled. A historical control cohort will be established to evaluate the efficacy and safety of Firsekibart by comparing with historical data.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-24.
Trial Details
NCT Number NCT07502105
Lead Sponsor Tongji Hospital
Conditions Systemic Scleroderma
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20